We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

Within tumors in the human body, there are immune cells (macrophages) capable of fighting cancer, but they have been unable ...

The MarketWatch News Department was not involved in the creation of this content. MiniPRO(TM) - Independent Control of up to 24 Cultures for Scalable, Closed-System Cell Therapy Development CAMARILLO, ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

KAIST researchers have developed a way to reprogram immune cells already inside tumors into cancer-killing machines. A drug ...

Formerly Somite AI, the rebranded company aims to broaden the regenerative medicine landscape by building AI models that ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

Cell and gene therapy are revolutionary approaches to treating diseases at the molecular level. They involve the manipulation ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show the treatment is safe and can significantly improve vision, even in severely ...